

## P2 Growth Restriction on an *rpoC* Mutant Is Suppressed by Alleles of the *Rz1* Homolog *lysC*

Dmitry Markov,<sup>1</sup> Gail E. Christie,<sup>2</sup> Brian Sauer,<sup>3†</sup> Richard Calendar,<sup>3</sup> Taehyun Park,<sup>4</sup> Ry Young,<sup>4</sup> and Konstantin Severinov<sup>1\*</sup>

Waksman Institute and Department of Molecular Biology and Biochemistry, State University of New Jersey, Rutgers, Piscataway, New Jersey 08854<sup>1</sup>; Department of Microbiology and Immunology, Virginia Commonwealth University, Richmond, Virginia 23298<sup>2</sup>; Department of Molecular and Cell Biology, University of California, Berkeley, California 94720<sup>3</sup>; and Department of Biochemistry and Biophysics, Texas A&M University, College Station, Texas 77843-2128<sup>4</sup>

Received 16 February 2004/Accepted 14 April 2004

*Escherichia coli* strain 397c carries a temperature-sensitive mutation, *rpoC397*, that removes the last 50 amino acids of the RNA polymerase  $\beta'$  subunit and is nonpermissive for plating of bacteriophage P2. P2 *gor* mutants productively infect 397c and define a new gene, *lysC*, encoded by a reading frame that extensively overlaps the P2 lysis accessory gene, *lysB*. The unusual location of *lysC* with respect to *lysB* is reminiscent of the *Rz/Rz1* lysis gene pair of phage  $\lambda$ . Indeed, coexpression of *lysB* and *lysC* complemented the growth defect of  $\lambda$  *Rz/Rz1* null mutants, indicating that the *LysB/C* pair is similar to *Rz/Rz1* in both gene arrangement and function. Cells carrying the *rpoC397* mutation exhibited an early onset of P2-induced lysis, which was suppressed by the *gor* mutation in *lysC*. We propose that changes in host gene expression resulting from the *rpoC397* mutation result in changes in the composition of the bacterial cell wall, making the cell more susceptible to P2-mediated lysis and preventing accumulation of progeny phage sufficient for plaque formation.

During bacteriophage infection, the machinery for macromolecular synthesis in the cell is recruited to serve the needs of the virus, and systematic changes in viral gene expression take place in a defined sequence. Bacterial DNA-dependent RNA polymerase (RNAP; subunit composition,  $\alpha_2\beta\beta'\omega\sigma$ ), the enzyme responsible for most host transcription, is a major target of this regulation (14). Thus, mutations in RNAP *rpo* genes often specifically prevent bacteriophage development. To date, mutations that interfere with bacteriophage development have been identified in genes coding for all RNAP subunits except the smallest subunit,  $\omega$  (reviewed in reference 34). Some of these mutations define RNAP sites that interact directly with viral regulators (25, 26, 40), while others affect phage gene expression indirectly by altering the properties of RNAP, such as the efficiency of transcription termination (39). The power of phage genetics, allowing isolation of suppressor mutations that overcome the blocks conferred by the changes in RNAP, has been invaluable in the study of these phenomena, and the results have greatly enriched our understanding of the basic processes of transcription (27).

From this perspective, the block against plaque formation for phages P2 (10) and N4 (25) conferred by the *rpoC397* mutation has long been provocative. This mutation removes 16 bp close to the end of *rpoC*, resulting in the replacement of the last 50 amino acids of RNAP subunit  $\beta'$  with 23 incorrect residues (10). In addition to being nonpermissive for the two phages, *Escherichia coli* strain 397c, carrying *rpoC397*, has a

gross temperature-sensitive (Ts) growth phenotype. Based on biochemical experiments, the N4 block appears to be due to the loss of a contact between N4 SSB (single-strand DNA binding protein) and  $\beta'$  that is required for activation of viral late transcription (25). However, the mechanism by which the *rpoC397* mutation prevents P2 growth has not been determined. Here, we report genetic and physiological experiments addressing this issue and discuss the surprising results in terms of the timing of host lysis.

### MATERIALS AND METHODS

**Bacterial strains, plasmids, phages, and molecular cloning.** The strains, plasmids, phages, and oligonucleotides used throughout this work are listed in Table 1. Luria-Bertani (LB) medium (4) was the standard culture medium, supplemented as appropriate where indicated.

P2 *lysC*, or *lysB/lysC*, *lysB/lysC(gor)* or *lysB/lysC(Am)* pairs were amplified by PCR from P2 lysates and cloned between the *NdeI* and *XhoI* sites of pCYB2. Since pCYB2 allows substantial expression of structural genes even in the absence of induction (28), all experiments were conducted without IPTG (isopropyl- $\beta$ -D-thiogalactopyranoside).

pUCF4 is a pUC8 derivative carrying the P2 late promoter pF (12). Plasmid pGC160 carries the P2 lysis region (nucleotides [nt] 6695 to 8544) under pF control. This region was amplified from P2 *vir-1* with primers *Lys5* and *Lys3*, using Pfu Turbo DNA polymerase, digested with *BamHI* and *PstI*, and ligated with pUCF4 cleaved with the same two enzymes. Plasmid pGC163 was made the same way, using the equivalent fragment amplified from P2 *gor-1*.

To construct pTG257, a plasmid that carries an IPTG-inducible copy of the P2 *ogr* gene, a 400-bp *XhoI*-*HindIII* fragment containing the *ogr* gene under the control of a variant T7A1 promoter with two *lac* operators ( $P_{\Delta 1/03/04}$ ) (21) was isolated from plasmid pBJ49 (18). This fragment was inserted at the unique *BamHI* site of pRG1, a derivative of pACYC177 (7) containing a 1.2-kb *PstI* fragment encoding *lacI<sup>q</sup>* (Robert Garcea, unpublished observation). Both the fragment and linearized pRG1 were filled-in with Klenow polymerase prior to ligation.

**Activation of a cloned P2 late promoter.** Chloramphenicol acetyltransferase (CAT) expression was assayed in cultures of P90A5c and 397c carrying either the P2 late promoter expression plasmid pFCAT100 (15) and the IPTG-inducible P4 Delta plasmid pDEB50 (9) or carrying pSL130 (22), a control plasmid expressing

\* Corresponding author. Mailing address: Waksman Institute for Microbiology, 190 Frelinghuysen Rd., Piscataway, NJ 08854. Phone: (732) 445-6095. Fax: (732) 445-5735. E-mail: severik@waksman.rutgers.edu.

† Present address: Stowers Institute for Medical Research, Kansas City, MO 64110.

TABLE 1. Bacterial strains, plasmids, phages, and primers used in this study

Strain, plasmid, bacteriophage, or primer	Genotype/relevant features	Source or reference
<b>Strains</b>		
<i>E. coli</i> K-12		
P90A5c	Prototrophic; parent of 397c	Christie et al. (10)
397c	Ts; carries <i>rpoC397</i> deletion	Christie et al. (10)
SA1030	<i>his strA gal-3</i>	Adhya and Shapiro (1)
AD1600	<i>his strA gal-3 rho(Ts)I5</i>	Das et al. (13)
DH5 $\alpha$	Auxotrophic r <sub>K</sub> <sup>-</sup> m <sub>K</sub> <sup>+</sup>	BRL Life Technologies
MC4100	<i>araD139<math>\Delta</math>(argF-lac)U169 thiA1 rpsL150 relA1 deoC1 PtsF25 rbsR ffbB5301</i>	Zhang and Young (43)
RW4206	Met <sup>+</sup> <i>rpoC</i> <sup>+</sup> transductant of MG1655 <i>metA</i>	Robert Weisberg
RW4204	Met <sup>+</sup> <i>rpoC397</i> transductant of MG1655 <i>metA</i>	Robert Weisberg
<i>E. coli</i> C		
C-1a	Prototrophic F <sup>-</sup>	Sasaki and Bertani (32)
C-520	<i>supD</i> F <sup>+</sup> ; P2 indicator	Sunshine et al. (36)
C-4508	Auxotrophic F <sup>-</sup>	King et al. (20)
C-4517	C4508 <i>supD</i>	King et al. (20)
C-4518	C4508 <i>supF</i>	King et al. (20)
<b>Plasmids</b>		
pCYB2	Expression vector	New England Biolabs
pCYB2 <i>lysB</i> <sup>+</sup>		This work
pCYB2 <i>lysC</i> <sup>+</sup>		This work
pCYB2 <i>lysC(trl)</i>		This work
pCYB2 <i>lysC(gor)</i>		This work
pCYB2 <i>lysB</i> <sup>+</sup> <i>lysC</i> <sup>+</sup>		This work
pCYB2 <i>lysB</i> <sup>+</sup> <i>lysC(gor)</i>		This work
pCYB2 $\beta'$	<i>rpoC</i> <sup>+</sup> expression vector	Nedea et al. (28)
pCYB2 $\beta'$ 397c	<i>rpoC397</i> expression vector	This work
pBBRV7	P2 EcoRV fragment (6290–8378) in pUC18/HincII	Ziermann et al. (44)
pDEB50	Delta expression vector with modified T7A1 (P <sub>A1/04/03</sub> ) promoter and <i>lacI</i> <sup>q</sup>	Christie et al. (9)
pFCAT100	P2 pF- <i>cat</i> expression plasmid	Grambow et al. (15)
pGC160	pUCF4 with wild-type P2 lysis cassette	This work
pGC163	pUCF4 with P2 <i>gor</i> lysis cassette	This work
pGCRV7 <i>gor-1</i>	P2 <i>gor-1</i> EcoRV fragment (6290–8378) in pUC18/HincII	This work
pNL130	P2 BstEII fragment (7455–8862) in pUC9/HincII	Linderoth et al. (24)
pSL130	P <sub>lac</sub> <i>cat</i> expression plasmid	Li et al. (22)
pTG257	Ogr expression vector with modified T7A1 (P <sub>A1/04/03</sub> ) promoter and <i>lacI</i> <sup>q</sup>	This work
pTG605	pNL130 with <i>lysC</i> (Am) mutation	This work
pUC18	Cloning vector	Norrander et al. (29)
pUCF4	pUC8 carrying P2 pF promoter	Christie and Calendar (12)
pRG1	pACYC177/PstI with 1.2-kb PstI fragment carrying <i>lacI</i> <sup>q</sup>	Robert Garcea
<b>Bacteriophages</b>		
P2 <i>vir-22</i>	Immunity insensitive	Chattoraj and Inman (8)
P2 <i>vir-22 gor-1</i>	Spontaneous mutant; plates on AD1600, 397c	This work
P2 <i>vir-22 trl-21</i>	Spontaneous mutant, plates on 397c	This work
P2 <i>vir-22 trl-22</i>	Spontaneous mutant, plates on 397c	This work
P2 <i>vir-1</i>	Clear plaque mutant	Bertani (5)
P2 <i>vir-1 R</i> (Am)3	Tail assembly defect	Lindahl (23)
P2 <i>vir-1 lysC</i> (Am)		This work
186 c(Ts)		Baldwin et al. (2)
Hy5	P2/186 hybrid	Hocking and Egan (17)
$\lambda$	<i>stf::cat::tfa cI857</i>	Zhang and Young (43)
$\lambda$ Rz(Am) Rz1 <sup>+</sup>		Zhang and Young (43)
$\lambda$ Rz <sup>+</sup> Rz1(Am)		Zhang and Young (43)
$\lambda$ Rz(Am) Rz1(Am)		Zhang and Young (43)
<b>Primers<sup>a</sup></b>		
MR2	GCACGCCAGTGATTGTC	Linderoth et al. (24)
28am	ACGGCGATTTATAGGCCGATATCCGG	This work
lysB_Up	CATATGTCAAGGCTGATGATTG	This work
lysC_Up	CATATGAGAACGAAGATTTTCG	This work
lysC_Down	CTCGAGTCAGTCAGCGCCCTGCGCA	This work
Lys3	GAACTGCAGTCAATCCACGAATATCCGCAG	This work
Lys5	CGAGGATCCGTCAATCTGTGGGAGTAAC	This work

<sup>a</sup> Primer sequences are given 5'→3'.

*cat* from the *tac* promoter, and the compatible *lacI*<sup>q</sup> plasmid pRG1. Cultures were grown in LB medium supplemented with ampicillin (100 µg/ml) and kanamycin (60 µg/ml) to an  $A_{600}$  of 0.5 and induced by the addition of IPTG to 1 mM. Forty-five minutes after induction, duplicate cultures were lysed by sonication and CAT activity was determined spectrophotometrically and normalized to the protein concentration, as described previously (15). The values given represent the average of at least three determinations on two separate cultures.

**P2 complementation by plasmid-encoded proteins.** Overnight *E. coli* cultures were inoculated into 100 volumes of LB medium containing 2 mM CaCl<sub>2</sub> and 2 mM MgCl<sub>2</sub> and grown at 30°C to an optical density at 600 nm ( $OD_{600}$ ) of 0.5 (ca. 3 to 5 h). One hundred microliters of cell culture was mixed with 100 µl of 10 mM Tris-HCl (pH 7.9), 1% (wt/vol) NaCl, 2 mM MgCl<sub>2</sub>, and 2 mM CaCl<sub>2</sub> containing ca. 500 to 1,000 PFU of P2 and incubated for 7 min at 30°C. Cell-phage suspensions were mixed with 2 ml of molten 0.6% LB top agar and poured over the surface of 60-mm-diameter plates containing 10 ml of hardened 1.5% LB bottom agar. Both top agar and bottom agar contained 2 mM CaCl<sub>2</sub>. For plasmid-carrying strains, ampicillin was added to the medium at a final concentration of 200 µg/ml. Plates were incubated face up overnight at various temperatures. Phage plaques and cleared zones were recorded with a Nikon SMZ-U binocular microscope attached to a Hitachi KP-D50 digital camera (zoom, 1:10).

**Construction of a P2 *lysC*(Am) mutant.** An amber mutation in the putative *lysC* open reading frame was introduced into the sequence between *lysB* and gene *R*, at P2 nt 8370 to 8372, by incorporation of a phosphorylated mutant oligonucleotide during PCR amplification. DNA was amplified from pNL130 by using 100 ng each of the P2 primer MR2 and the *lacZ* primer 1212 (New England Biolabs), and 1,000 ng of phosphorylated mutagenic primer 28am. PCR was carried out with Vent DNA polymerase in the presence of Taq DNA ligase (both from New England Biolabs). The full-length PCR product was gel purified, digested with EcoRI and SphI, and used to replace the corresponding EcoRI-SphI fragment in pNL130. The mutation in the resulting plasmid, pTG605, was verified by sequence analysis and introduced into the genome of P2 *vir-1* by homologous recombination, using rescue of P2 *vir-1* R(Am)3 (which has a Ts phenotype on *supD* strains), as described by Ziermann et al. (44).

**Marker rescue.** For rescue of the cloned *gor-1* or *lysC*(Am) mutations, P2 phages were grown in permissive strains carrying the plasmid with the desired mutation. Phage lysates were treated with UV light to 50% survival prior to infection to enhance recombination. Following infection, the progeny phage was then plated on both permissive and nonpermissive strains to assess the frequency of rescue and to select the desired recombinant phages.

**Burst size determination.** *E. coli* strain C-1a was grown with shaking at 37°C in LB medium supplemented with 0.2% glucose (LBglc) to a value of 50 Klett units. Cells were concentrated twofold in LBglc supplemented with 5 mM CaCl<sub>2</sub> and infected with P2 or P2 *lysC*(Am) at a multiplicity of infection of 5. After 8 min of incubation, the infected cells were diluted 10-fold into LBglc containing anti-P2 serum (K value of approximately 6 [first-order inactivation constant]), incubated for an additional 8 min, and then diluted 10<sup>-4</sup> into LBglc. An aliquot was removed immediately, and the titer was determined on strain C-520 to determine the number of infected cells. The culture was incubated with shaking at 37°C for 60 min, and the titer was determined again on C-520.

**λ prophage construction and induction.** The λ prophages containing *Rz* and/or *RzI*(Am) mutations carry chloramphenicol resistance and are thermally inducible (43). Phage lysates were prepared from logarithmically growing lysogens of *E. coli* MC4100 by induction for 15 min at 43°C, followed by aeration at 37°C for 40 to 60 min or until visible lysis occurred. After the addition of 1% (vol/vol) chloroform and 10 mM MgCl<sub>2</sub>, cultures were vigorously vortexed for 20 s, incubated at 37°C for 30 min, and clarified by low-speed centrifugation. The cleared phage lysates were stored at 4°C.

**Lysis induction by the cloned P2 lysis cassette.** *E. coli* strains transformed with the *Ogr* expression plasmid pTG257 and a compatible lysis region plasmid or vector control were grown at 30°C in LB medium containing ampicillin (100 µg/ml) and kanamycin (60 µg/ml) to a value of ~50 Klett units. Expression of *ogr* was induced by the addition of IPTG to 1 mM, and lysis was monitored by measuring the OD of the culture. Each lysis plasmid was assayed at least six times from a minimum of three independent transformants.

## RESULTS

**The P2 growth defect depends on the Ts phenotype of the *rpoC* deletion.** To assess whether the *rpoC397* mutation was sufficient for the growth defect of P2 on strain 397c, isogenic plasmids constitutively expressing the wild-type *rpoC* allele or




FIG. 1. The *rpoC397* mutation interferes with bacteriophage P2 growth. A plasmid-encoded RNAP  $\beta'$  subunit complements the P2 plating defect on a 397c host. Bacteriophage P2 was used to infect lawns of 397c or its *rpoC*<sup>+</sup> parent, P90A5c, harboring plasmids expressing wild-type *rpoC*, *rpoC* carrying the 397c mutation or control vector plasmid. The results of overnight plating at 30°C are presented.

the *rpoC397* allele were introduced into both the wild-type and the 397c hosts and the transformants were tested for plaque-formation by P2. The experiment presented in Fig. 1 shows that wild-type *rpoC* expressed from a plasmid complemented the *rpoC397* block to P2, whereas a plasmid carrying the mutant *rpoC* gene did not. P2 growth in the wild-type *rpoC* host was unaffected by the presence of the *rpoC397* plasmid, indicating that the *rpoC* defect is recessive. Thus, the lesion in RNAP is solely responsible for the P2 growth defect exhibited by the 397c cells and is recessive to the wild type.

If the nonpermissive phenotype for P2 was due to a lack of an interaction between a phage transcription factor and the mutant RNAP present in 397c, then Ts<sup>+</sup> revertants of the *rpoC* deletion mutant should retain the plating defect. However, a spontaneous Ts<sup>+</sup> derivative of 397c efficiently plated P2 *vir-1*, but still contained the deletion, as indicated by the presence of the shortened  $\beta'$  subunit (Fig. 2). The result therefore suggests that in contrast to N4 (25), P2 is unlikely to encode a transcription factor that directly interacts with the portion of  $\beta'$  removed by the *rpoC397* deletion.

Initial efforts to elucidate the P2 growth defect conferred by the *rpoC397* mutation included assessing the effects of this mutation on P2 DNA replication and transcription. Formation of pulse-labeled, covalently closed circular P2 DNA following infection at 33°C was assayed by CsCl-ethidium bromide density gradient centrifugation, and the levels were found to be similar in both P90A5c and 397c; the identity of this newly synthesized DNA was further confirmed by EcoRI restriction (33; data not shown). Since P2 DNA replication is dependent upon P2 early gene products, this implies that P2 early transcription is also not impaired in 397c. P2 late gene transcription is normally activated by the P2 *Ogr* protein, used during P2 lytic infection, or by the related Delta protein of satellite phage P4, which stimulates high levels of P2 late gene expression when P2 is serving as a helper for P4 lytic growth (reviewed in reference 11). To examine the effect of the *rpoC397* mutation on initiation of P2 late transcription, Delta-dependent expression of *cat* from the P2 late promoter P<sub>F</sub> was assayed in P90A5c and 397c and compared to that of a control plasmid in which *cat* was expressed from the *tac* promoter. For the *tac* promoter, *cat* expression was reduced slightly in 397c,






FIG. 2. P2 plates on a  $Ts^+$  pseudorevertant of 397c. A spontaneous revertant of *E. coli* 397c able to form colonies at 42°C was isolated. (Top panel) Proteins from whole-cell lysates of *rpoC*<sup>+</sup> strain P90A5c, the 397c mutant, and the 397c  $Ts^+$  revertant were resolved by electrophoresis on a 5% sodium dodecyl sulfate gel and visualized by Coomassie staining. The portion of the gel containing the  $\beta$  and  $\beta'$  subunits is shown. (Bottom panel) Bacteriophage P2 was used to infect lawns of the indicated cells. The results of overnight growth at 30°C are presented.

to 74% of the level seen in P90A5c. A slightly larger effect on expression from  $P_F$  was seen; in 397c, the CAT activity was 44% of that obtained in P90A5c. It is likely that this larger reduction is due to a combined nonspecific effect on expression of P4 Delta from pDEB50 and on subsequent Delta-dependent expression from  $P_F$ . We conclude that in contrast to the late transcription defect imposed by the *rpoA109* mutation, which prevents an essential interaction between the RNAP  $\alpha$  subunit and Ogr or Delta and reduces expression from  $P_F$  by about 2 orders of magnitude (15), the *rpoC397* mutation does not appear to confer a specific block to P2 late transcription.

**P2 mutations that allow growth on 397c define a new gene.**

To determine the basis of the P2 plating defect, spontaneous suppressor mutants that formed plaques on 397c lawns were obtained. One class of suppressors, called *trl*, was isolated directly by plating on 397c lawns at 30°C. A second class of mutants, called *gor*, were originally isolated based on their ability to overcome a block to P2 growth imposed by the

*rho(Ts)15* mutation in *E. coli* strain AD1600 (13) and were found to plate on 397c as well. The suppression was not reciprocal: while the P2 *gor* mutants formed plaques on 397c lawns, P2 *trl* mutants did not form plaques on AD1600 lawns (Table 2).

The *rpoC397* mutation did not affect growth of the P2-related phage 186, but growth of the hybrid phage Hy5, which carries the early region of 186 and the late region of P2 (17), was blocked (Table 2), suggesting that the *trl* mutations map to the P2 late genes. Indeed, three factor crosses (33; data not shown) placed the *trl* and *gor* mutations between P2 genes *K* and *R*, in a region encoding host lysis and tail functions. A cloned 2.1-kb EcoRV fragment spanning the lysis region (P2 coordinates 6290 to 8378; GenBank accession no. AF063097; see also reference 43) from P2 *gor1* rescued the plating of wild-type P2 on 397c (data not shown). The DNA sequence of this region from *gor1* and from two independent *trl* isolates was determined and compared to the wild-type P2 sequence. The two *trl* mutants had a single, identical nucleotide change, from C to A at nt 8274, and the *gor1* mutant also had a single-nucleotide change, which was immediately adjacent to the *trl* substitution, from C to T at nt 8275. These changes fall within *lysB*, encoding a nonessential lysis gene (44), and also within an overlapping +1 reading frame, spanning P2 coordinates 8202 to 8492. This reading frame is preceded by a good Shine-Dalgarno sequence and potentially encodes a proline-rich protein (10 Pro residues in 96 amino acids). The first half of this open reading frame is embedded within the last 48 codons of *lysB*; the end of this reading frame extends into the tail gene *R* (Fig. 3A). Originally designated orf28 by Portelli et al. (31), this reading frame was predicted to be another nonessential lysis gene, *lysC*, and to encode a homolog of the  $\lambda$  Rz1 lysis protein (43). Since the *gor* mutation is silent within *lysB*, the suppression of the Gro<sup>-</sup> phenotype of 397c by the *gor* and *trl* mutations must be due to the changes in *lysC* (Pro 25 Leu and Pro 25 Thr for *gor* and *trl*, respectively; Fig. 3A). This result indicates that *lysC* does encode a P2 protein. Although sequence similarity between LysC and Rz1-like proteins is not significant, inspection of the LysC primary structure reveals a consensus signal peptidase II cleavage site (Fig. 3A) and a high proportion of Pro residues, both characteristic of all Rz1 protein sequences (43). These considerations, the unique intragenic embedding of *lysC* and *Rz1*, and the results of functional analysis presented below strongly indicate that LysC and Rz1 are evolutionarily homologous, as first suggested by Zhang et al. (43).

TABLE 2. Plating of P2 and related phages on strains carrying the *rpoC397* and *rho(Ts)15* mutations

Phage	Efficiency of plating <sup>a</sup>			
	P90A5c ( <i>rpoC</i> <sup>+</sup> )	397c ( <i>rpoC397</i> )	SA1030 ( <i>rho</i> <sup>+</sup> )	AD1600 [ <i>rho(Ts)15</i> ]
P2 <i>vir-1</i>	1.0	$1 \times 10^{-7}$	1.0	$4 \times 10^{-9}$
186 <i>cI(Ts)</i>	1.0	1.0	1.0	1.0
Hy5 (P2/186 hybrid)	1.0	$1 \times 10^{-7}$	1.0	$<1 \times 10^{-9}$
P2 <i>vir-1 trl-1</i>	1.0	1.0	1.0	$<1 \times 10^{-7}$
P2 <i>vir-22 L(Ts)37 gor-3<sup>b</sup></i>	1.0	1.0	1.0	0.21

<sup>a</sup> All platings were performed at 33°C.

<sup>b</sup> The *vir-22* and *L(Ts)37* mutations do not affect P2 growth under the conditions used and were employed to facilitate mapping of the *gor* mutation. Hy5 also carries the 186 *cI(Ts)* mutation.




FIG. 3. P2 mutants that grow on 397c define a new gene, *lysC*. (A) Map of the bacteriophage P2 lysis region. The P2 genome coordinates of the EcoRV fragment used to rescue the *trl* and *gor* mutations are indicated, as are the relative locations of the genes in this region. The amino acid sequence of the *lysC* reading frame is shown below the map, and the amino acid sequence changes resulting from the *trl* and *gor* mutations are indicated below the sequence. The PP dipeptide characteristic of all Rz1 proteins is underlined. Also shown for comparison is the amino acid sequence of  $\lambda$  Rz1. Gray arrows indicate the putative signal peptidase II cleavage sites in the two proteins. (B) Overexpression of *lysC* harboring *gor* or *trl* mutations, but not wild-type *lysC*, is sufficient to overcome the plating defect of P2. 397c or P90A5c cells harboring plasmids expressing wild-type *lysC*, *lysC* carrying the *gor* or *trl* mutations, or control vector plasmid pCYB2 were infected with wild-type P2 (top) or a P2 mutant carrying an amber mutation in *lysC* (bottom). The results of overnight growth at 30°C are presented.

In order to obtain further evidence as to whether *lysC* represented a protein-coding gene, we introduced an amber mutation in place of codon 57 (P2 coordinates 8370 to 8372). This nonsense mutation does not alter the predicted amino acid sequence of LysB, yet it showed a distinct suppressible plating phenotype, plating with normal plaque size on *supD* or *supF* strains but with a tiny plaque size on nonsuppressing hosts, indicating that *orf28* encodes a protein. A comparison of the burst size of this mutant with that of P2 *vir-1* in a nonsuppressing host showed less than a twofold reduction (124 for the amber mutant versus 200 for P2 *vir-1*), suggesting that the plating phenotype might be related to host lysis, rather than

the intracellular production of virions. Taken together, these data further strengthen the conclusion that *lysC*, previously *orf28*, is a P2 gene encoding an Rz1-like protein product.

To confirm that the *lysC* mutations are sufficient to overcome the P2 plating defect on 397c cells, we created plasmids that expressed the wild-type, *trl*, or *gor* alleles of *lysC* from the *tac* promoter. These plasmids were introduced into 397c cells, and their ability to complement the plating defect of wild-type P2 was determined. Expression of the wild-type *lysC* had no effect on P2 growth. In contrast, expression of *lysC(gor)*, and to a lesser degree *lysC(trl)*, allowed plaque formation (Fig. 3B). The suppressing effect of the plasmid-borne *lysC(trl)* allele was




FIG. 4. Co-overexpression of bacteriophage P2 *lysB* and *lysC* complements the lysis defect caused by bacteriophage  $\lambda Rz$  and/or *RzI* mutations. Logarithmically growing *rpoC<sup>+</sup>* P90A5c cells lysogenic for  $\lambda Rz^+/RzI^+$  or the indicated *Rz* and/or *RzI*  $\lambda$  mutants were thermally induced for 15 min at 43°C (hatched area) and then transferred to 37°C. Cell lysis was monitored spectrophotometrically. The values presented are mean values from three independent experiments. Different panels represent lysis curves obtained with induced lysogens harboring plasmids expressing *lysC* (pCYB2*lysC*) (A), *lysB* (pCYB2*lysB*) (B), or coexpressing wild-type *lysB* and *lysC* (pCYB2*lysB*, *lysC*) (C).




FIG. 5. *lysC gor* delays host lysis. Logarithmically growing RW4206 (*rpoC*<sup>+</sup>) (A) or RW4204 (*rpoC397*) (B) *E. coli* cells carrying the *ogr* expression plasmid pTG257 and either pUCF4 (vector control), pGC160 (*lysC*<sup>+</sup>), or pGC163 (*lysC*<sup>gor</sup>) plasmids with P2 lysis genes under the control of the P2 pF promoter were induced with IPTG, and cell lysis was monitored spectrophotometrically. Curves representative of the results from six independent experiments are shown.

more pronounced in P2*lysC*(Am) infections (Fig. 3B). This suggests that the wild-type *LysC* may be inhibiting the function of the *LysC*(*trl*) mutant.

**P2 *LysB/C* complements  $\lambda$  Rz/Rz1 lysis defects.** The *lysC* gene and its overlapping arrangement with *lysB* are conserved in closely related P2-like phages, including 186, W $\phi$ , L-413C, Fels-2, SopE $\phi$ , and PSP3, as well as in the more distantly P2-related *Pseudomonas aeruginosa* phage  $\phi$ CTX. No significant sequence similarity is found with other genes in the database. *Rz1* genes are always found embedded within *Rz* genes (30, 41, 43), so *lysC* and *lysB* may be similar to *Rz1* and *Rz* genes, respectively. In  $\lambda$  and P22, *Rz* and *Rz1* are both required for lysis if the host envelope is stabilized by millimolar concentrations of divalent cations. *Rz1* is a lipoprotein, processed by signal peptidase II, and *LysC* has an appropriately placed Cys residue, which could serve as part of a signal peptidase II motif. Moreover, although there is no significant

amino acid sequence similarity between *LysC* and *Rz1*, both are rich in Pro residues. To establish whether *LysB/C* and *Rz/Rz1* have analogous functions, we introduced plasmids carrying *lysB*, *lysC*, or both genes into *E. coli* cells lysogenic for wild-type  $\lambda$  or various  $\lambda$  *Rz/Rz1* mutants (43) and subjected the transformants to thermal induction in the presence of 10 mM MgCl<sub>2</sub>. As expected, lysis was observed in the induction of the *Rz*<sup>+</sup> *Rz1*<sup>+</sup> lysogen, but not in *Rz*(Am), *Rz1*(Am), and *Rz*(Am) *Rz1*(Am) (data not shown; see also reference 43). This lysis defect was complemented by a plasmid coexpressing *lysB* and *lysC*, but not by plasmids expressing *lysB* or *lysC* alone (Fig. 4). In the *lysB*- and *lysC*-complemented inductions, lysis kinetics were somewhat delayed for both *Rz*(Am) lysogens, whereas the *Rz*<sup>+</sup> *Rz1*(Am) lysogen underwent lysis at the same time as the parental lysogen (Fig. 4). We conclude that P2 *LysB/LysC* can functionally substitute for  $\lambda$  *Rz/Rz1*, but neither *LysB* nor *LysC* alone can complement either an *Rz* or *Rz1* defect.

***lysC* mutations delay host lysis.** Efforts to monitor P2-induced lysis directly in strains carrying *rpoC397* are complicated by the relatively poor adsorption of P2 to *E. coli* K-12 strains, which precludes analysis of one-step growth curves (our unpublished data), and by the apparent incompatibility of *rpoC397* with *E. coli* C, in which P2 is normally studied (33). In order to circumvent these technical limitations, we assayed P2-induced host cell lysis by using expression plasmids carrying the entire lysis gene cassette (*YK lysABC*). Tight control of these otherwise toxic genes was achieved by regulation of this cassette by using the P2 late promoter P<sub>F</sub>. Expression from P<sub>F</sub> was regulated by the P2 late transcription factor Ogr, which was supplied in *trans* from compatible plasmid pTG257, carrying an IPTG-inducible copy of the P2 *ogr* gene. The *ogr* gene in this construct was expressed from the same promoter used for expression of P4 Delta in the *cat* assays described above, and, accordingly, should be expressed in *rpoC397* cells, albeit at a slightly reduced level. Ogr was chosen instead of Delta for these experiments because it is a less efficient activator of P<sub>F</sub>, thus minimizing the potentially lethal effects of any leaky activator expression in the absence of IPTG induction.

The otherwise isogenic *E. coli* strains RW4206 (*rpoC*<sup>+</sup>) and RW4204 (*rpoC397*) carrying pTG257 and plasmids with either the wild-type (pGC160) or *gor-1* (pGC163) alleles of *lysC* were grown to early logarithmic phase at 30°C and induced with IPTG (Fig. 5). In the *rpoC*<sup>+</sup> host, the wild-type lysis cassette caused a cessation of growth at about 30 min after induction, and overt lysis was observed beginning at about 45 min. The same plasmid caused cessation of growth significantly earlier in the *rpoC397* host, and gradual lysis was detectable by 25 min after induction. This was surprising, especially in light of the fact that we expected expression of the plasmid-encoded lysis cassette to be slightly reduced in this strain compared to that in the *rpoC* strain. The early cessation of growth was reproducible and may indicate that some cells started to lyse at this point, while others continued to grow. In contrast, the expression of the lysis cassette carrying *lysC*(*gor*) resulted in an extended growth period and delayed lysis in both the parental and *rpoC397* backgrounds—especially in the latter, where growth continued until lysis was apparent at about 70 min after induction.

We conclude that the primary effect of the *lysC*(*gor*) allele is a delay in the onset of lysis. Accordingly, we propose that early



onset of lysis observed with the wild-type lysis cassette in the *rpoC397* background underlies the plating defect of P2 on this host, and that the suppressor effect of the *gor* mutation derives from a delay in lysis that allows accumulation of phage progeny sufficient for plaque formation.

## DISCUSSION

**Identification of the P2 *lysB* and *lysC* genes as functional homologs of *Rz* and *Rz1*.** We report here the genetic identification and initial characterization of a new P2 gene, *lysC*. P2 *lysC* mutants suppress the defect to P2 growth conferred by the *E. coli rpoC397* mutation in RNAP. A defect in interaction between a viral activator of late transcription and the mutant RNAP has been proposed to explain the reported inability of bacteriophage N4 to grow on 397c (25). We therefore expected that P2 phages that grow on 397c would also carry mutations in genes whose products interact with RNAP and affect viral gene expression. However, the experiments presented here strongly suggest that LysC is not involved in transcription regulation but instead plays a role, together with its partner protein LysB, in host lysis.

It was proposed previously by one of us that the LysB/LysC pair is homologous to Rz/Rz1 based on unusual amino acid composition and the overlapping organization of these genes (43). Both Rz1 and LysC are relatively short polypeptides containing an unusually high proportion of Pro residues (11 of 79 and 10 of 96, respectively). The N-terminal domains of both proteins contain putative signal peptidase II motifs, indicating that both are processed to lipoprotein forms, resulting in short (60 and 76 amino acids, respectively) polypeptides predicted to be attached to the inner leaflet of the outer membrane by lipid residues on the N-terminal Cys of the mature polypeptide (43). However, neither LysB nor LysC is significantly related by standard or reiterative BLAST searches to Rz or Rz1 or in fact to any proteins except those encoded by closely related P2-like phages. Moreover, the  $\lambda$  *Rz1* reading frame is completely embedded within the *Rz* gene, while the longer *lysC* reading frame spans the end of *lysB*, the beginning of gene *R*, and the intervening 107 nt. Nevertheless, we show here that production of P2 LysB and LysC efficiently suppresses the  $\lambda$  cation-sensitive lysis defect caused by either *Rz* or *Rz1* mutations, indicating that P2 LysC and LysB and  $\lambda$  Rz1 and Rz have similar functions. Production of either LysB or LysC alone does not correct the lysis defect caused by *Rz* and/or *Rz1* mutations. This strongly implies that LysB and LysC form heteromeric complexes. A similar conclusion was reached about Rz and Rz1 interaction while comparing host lysis defects caused by *Rz*, *Rz1*, and *Rz/Rz1* double mutants (43). Moreover, two-hybrid analysis has shown that the Rz and Rz1 homologs from phage T7 interact (3). Our data suggest that interspecies complexes (i.e., LysB/Rz1) either do not form or are not functional. The presence of the  $\lambda$  Rz1 protein (in the absence of Rz) results in a retardation of lysis mediated by LysB/LysC complexes in the presence of high magnesium ion concentrations (Fig. 4C), perhaps because nonfunctional LysB/Rz1 complexes reduce the amount of functional LysB/LysC heteromers. Presumably, the unique overlapping organization of these genes imposes severe restrictions on their evolutionary variation and helps to ensure that they coevolve.

The functional role of Rz/Rz1 and their homologues, LysB/LysC, is not clear. Sequence analysis reveals that genes whose products are similar to Rz/Rz1 and/or LysB/LysC are widespread in double-stranded DNA phage genomes. The unusual nested or overlapping arrangement of the two genes, as well as their localization immediately after the main host lysis genes, is also conserved, suggesting that the two proteins play an important, evolutionarily conserved function. In vitro analysis by the Taylor group demonstrated that  $\lambda$  Rz1 is found in the outer membrane and that, as predicted from the primary structure analysis, Rz1 is processed and lipoylated (16, 19, 37). More recently, the same group reported that Rz1 promotes membrane fusion in vitro (6). However, the lysis phenotype in lambda remains unexplained. In vivo, bacteriophage  $\lambda$  mutants with lesions in either *Rz* or *Rz1* are defective in host lysis, but only in the presence of millimolar levels of divalent cations (43). In contrast, the *lysC*(Am) mutation severely affects plating efficiency and plaque morphology of P2 (Fig. 3), and P2 *lysB*(Am) mutants show a slightly retarded lysis phenotype (44), and in neither case is the presence of millimolar concentrations of divalent cations required. A model for Rz function has been proposed in which Rz, and by extension, Rz/Rz1, is involved in attacking links between the outer membrane and the murein (42). Under standard laboratory conditions, the phage endolysin degrades the peptidoglycan sufficiently to cause bursting of the infected cell, but in the presence of high levels of divalent cations, the outer membrane would be significantly stabilized, thus making further degradation of the envelope necessary. The lack of a cation effect in P2 may simply reflect that the K endolysin is not as efficient at murein degradation and thus has a constitutive partial requirement for the LysB/C function.

***lysC* alleles, the suppression of RNAP defects, and implications for lysis control.** How does the *rpoC397* mutation result in defective P2 development, and how do *lysC* missense mutations overcome this defect? Our initial working model was that the RNAP mutation directly affected transcription of viral genes, leading somehow to a lysis defect. However, the locations of the compensatory *trl* and *gor* mutations in a gene located near the 3' end of a long late transcription unit, coupled with the lack of a block to initiation of phage late transcription in an *rpoC397* strain, argue that the effect of the RNAP mutation would have to be on elongation or some kind of attenuation mechanism affecting lysis gene expression. Since cells carrying the *rpoC397* mutation appear susceptible to accelerated lysis rather than impaired lysis, one would have to further propose that the change in transcription affected the relative levels of the various lysis proteins to somehow bring about the observed change in timing and that one of the lysis proteins modulates this effect. We cannot formally rule out such a model, but it requires invoking a complicated hypothetical regulatory mechanism for which there is no direct evidence or precedent. An attractive alternative model envisions that *rpoC397* causes changes in host gene expression that alter bacterial physiology, including properties of the cell membrane and/or cell wall, and thus affects the timing of host lysis during bacteriophage P2 infection. Indeed, whole-genome transcription profiling of 397c cells shows that genes responsible for type I extracellular polysaccharide synthesis are dramatically overproduced (38), a typical stress response when the bacterial



envelope is compromised (35). Thus, in this scenario, 397c cells, with defective envelopes, lyse prematurely when infected with wild-type P2, reducing the burst size below the threshold required for plaque formation. The *gor* mutation dramatically delays the lysis of *rpoC397* cells, presumably allowing a sufficient number of progeny to accumulate in each round of infection to generate visible plaques.

Both *lysC* mutations that we describe here affect the same residue of LysC: a Pro at position 25, which is replaced by either Leu (*gor*) or Thr (*trl*). Unlike P2, the closely related coliphage 186 does form plaques on strain 397c and the AD1600 [*rho*(Ts)15] strain (33) (Table 2). The predicted phage 186 LysC has a Gln at residue 25 in place of Pro. Thus, 186 may be naturally *gor* (or *trl*). At present, it is premature to speculate how *gor* and *trl* mutants retard host lysis, lacking understanding of the function of the wild-type Rz/Rz1 and thus LysB/LysC, protein complexes. However, the results reported here are very significant in terms of the general picture of the phage-mediated lysis of gram-negative bacteria. Heretofore, the timing of lysis has been thought to be the exclusive province of the holin proteins, which are produced by all double-stranded DNA phages (41). In this sense, timing refers to the termination of the infection cycle, because when the holin triggers, the host membrane is disrupted and all macromolecular synthesis and assembly stops. Here, timing is strongly affected by the *lysC*(*gor*) allele, which allows an extended growth period and thus compensates for the abortive, truncated infective cycle in P2 infections of the *rpoC397* host. Thus for the first time, a gene other than a holin gene is implicated in lysis timing. Although it is premature to speculate on the mechanistic details of this effect, nevertheless these results may be evidence for the formation of a "lysis-some," a multiprotein complex spanning the envelope and including all the lysis proteins, the holin Y, endolysin K, and the LysB/LysC complexes (and perhaps LysB, a putative antiholin; T. Park and R. Young, unpublished observation). Future experiments defining biological and biochemical functions, as well as interacting molecular partners, of LysB/LysC and Rz/Rz1 should help resolve these issues.

#### ACKNOWLEDGMENTS

We thank Tina Goodwin for technical assistance and Robert Weisberg for the MG1655 *rpoC* derivatives.

This work was supported by NIH grant GM59295 and a Burroughs Wellcome Career Award to K.S., ACS grant RPG-92-008NP to G.E.C., and NIH grant GM27099 to R.Y. D.M. was postdoctoral fellow of the Charles and Johanna Busch Memorial Fund.

#### REFERENCES

- Adhya, S. L., and J. A. Shapiro. 1969. The galactose operon of *E. coli* K-12. I. Structural and pleiotropic mutations of the operon. *Genetics* **62**:231–247.
- Baldwin, R. L., P. Barrand, A. Fritsch, D. A. Goldthwait, and F. Jacob. 1966. Cohesive sites on the deoxyribonucleic acids from several temperate coliphages. *J. Mol. Biol.* **17**:343–357.
- Bartel, P. L., J. A. Roeklein, D. SenGupta, and S. Fields. 1996. A protein linkage map of *Escherichia coli* bacteriophage T7. *Nat. Genet.* **12**:72–77.
- Bertani, G. 1951. Studies on lysogeny. I. The mode of phage liberation by lysogenic *Escherichia coli*. *J. Bacteriol.* **62**:293–300.
- Bertani, L. E. 1957. The effect of the inhibition of protein synthesis on the establishment of lysogeny. *Virology* **4**:53–71.
- Bryl, K., S. Kedzierska, M. Laskowska, and A. Taylor. 2000. Membrane fusion by proline-rich Rz1 lipoprotein, the bacteriophage lambda Rz1 gene product. *Eur. J. Biochem.* **267**:794–799.
- Chang, A. C. Y., and S. N. Cohen. 1978. Construction and characterization of amplifiable multicopy DNA cloning vehicles derived from the P15A cryptic miniplasmid. *J. Bacteriol.* **134**:1141–1156.
- Chattoraj, D. K., and R. B. Inman. 1972. Position of two deletion mutations on the physical map of bacteriophage P2. *J. Mol. Biol.* **66**:423–434.
- Christie, G. E., D. L. Anders, V. McAlister, T. S. Goodwin, B. Julien, and R. Calendar. 2003. Identification of upstream sequences essential for activation of a bacteriophage P2 late promoter. *J. Bacteriol.* **185**:4609–4614.
- Christie, G. E., S. B. Cale, L. A. Isaksson, D. J. Jin, M. Xu, B. Sauer, and R. Calendar. 1996. *Escherichia coli rpoC397* encodes a temperature-sensitive C-terminal frameshift in the  $\beta'$  subunit of RNA polymerase that blocks growth of bacteriophage P2. *J. Bacteriol.* **178**:6991–6993.
- Christie, G. E., and R. Calendar. 1990. Interactions between satellite bacteriophage P4 and its helpers. *Annu. Rev. Genet.* **24**:465–490.
- Christie, G. E., and R. Calendar. 1985. Bacteriophage P2 late promoters. II. Comparison of the four late promoter sequences. *J. Mol. Biol.* **181**:373–382.
- Das, A., D. Court, and S. Adhya. 1976. Isolation and characterization of conditional lethal mutants of *E. coli* deficient in transcription termination factor *rho*. *Proc. Natl. Acad. Sci. USA* **73**:1959–1963.
- Geiduschek, E. P., and G. A. Kassavetis. 1988. Changes in RNA polymerase, p. 93–109. *In* R. Calendar (ed.), *The bacteriophages*, vol. 1. Plenum Press, New York, N.Y.
- Grambow, N. J., N. K. Birkeland, D. L. Anders, and G. E. Christie. 1990. Deletion analysis of a bacteriophage P2 late promoter. *Gene* **95**:9–15.
- Hanych, B., S. Kedzierska, B. Walderich, B. Uznanski, and A. Taylor. 1993. Expression of the Rz gene and the overlapping Rz1 reading frame present at the right end of the bacteriophage lambda genome. *Gene* **129**:1–8.
- Hocking, S. M., and J. B. Egan. 1982. Genetic characterization of twelve P2–186 hybrid bacteriophages. *Mol. Gen. Genet.* **187**:174–176.
- Julien, B., and R. Calendar. 1996. Bacteriophage PSP3 and  $\phi$ R73 activator proteins: analysis of promoter specificities. *J. Bacteriol.* **178**:5668–5675.
- Kedzierska, S., A. Wawrzynow, and A. Taylor. 1996. The Rz1 gene product of bacteriophage lambda is a lipoprotein localized in the outer membrane of *Escherichia coli*. *Gene* **168**:1–8.
- King, R. A., D. L. Anders, and G. E. Christie. 1992. Site-directed mutagenesis of an amino acid residue in the bacteriophage P2 Ogr protein implicated in interaction with *Escherichia coli* RNA polymerase. *Mol. Microbiol.* **6**:3313–3320.
- Lanzer, M., and H. Bujard. 1988. Promoters largely determine the efficiency of repressor action. *Proc. Natl. Acad. Sci. USA* **85**:8973–8977.
- Li, S. C., C. L. Squires, and C. Squires. 1984. Antitermination of *E. coli* rRNA transcription is caused by a control region segment containing lambda *nut*-like sequences. *Cell* **38**:851–860.
- Lindahl, G. 1971. On the control of transcription in bacteriophage P2. *Virology* **46**:620–633.
- Linderoth, N. A., B. Julien, K. Flick, R. Calendar, and G. E. Christie. 1994. Molecular cloning and characterization of bacteriophage P2 genes *R* and *S* involved in tail completion. *Virology* **200**:347–359.
- Miller, A., D. Wood, R. H. Ebright, and L. B. Rothman-Denes. 1997. RNA polymerase beta' subunit: a target of DNA binding-independent activation. *Science* **275**:1655–1657.
- Nechaev, S., and K. Severinov. 1999. Inhibition of *E. coli* RNA polymerase by bacteriophage T7 gene 2 protein. *J. Mol. Biol.* **289**:815–826.
- Nechaev, S., and K. Severinov. 2003. Bacteriophage-induced modifications of host RNA polymerase. *Annu. Rev. Microbiol.* **57**:301–322.
- Nedea, E. C., D. Markov, T. Naryshkina, and K. Severinov. 1999. Localization of *Escherichia coli rpoC* mutations that affect RNA polymerase assembly and activity at high temperature. *J. Bacteriol.* **181**:2663–2665.
- Norrandner, J., T. Kempe, and J. Messing. 1983. Construction of improved M13 vectors using oligodeoxynucleotide-directed mutagenesis. *Gene* **26**:101–106.
- Pedulla, M. L., M. E. Ford, T. Karthikeyan, J. M. Houtz, R. W. Hendrix, G. F. Hatfull, A. R. Poteete, E. B. Gilcrease, D. A. Winn-Stapley, and S. R. Casjens. 2003. Corrected sequence of the bacteriophage P22 genome. *J. Bacteriol.* **185**:1475–1477.
- Portelli, R., B. Dodd, Q. Xue, and J. B. Egan. 1998. The late-expressed region of the temperate coliphage 186 genome. *Virology* **248**:117–130.
- Sasaki, I., and G. Bertani. 1965. Growth abnormalities in Hfr derivatives of *Escherichia coli* strain C. *J. Gen. Microbiol.* **40**:365–376.
- Sauer, B. L. 1979. Regulation of late gene expression in the temperate coliphage P2. Ph.D. thesis. University of California, Berkeley, Calif.
- Severinov, K. 2000. RNA polymerase structure/function: insights into points of transcriptional regulation. *Curr. Opin. Microbiol.* **3**:118–125.
- Sledjeski, D. D., and S. Gottesman. 1996. Osmotic shock induction of capsule synthesis in *Escherichia coli* K-12. *J. Bacteriol.* **178**:1204–1206.
- Sunshine, M. G., M. Thorn, W. Gibbs, R. Calendar, and B. Kelly. 1971. P2 phage amber mutants: characterization by use of a polarity suppressor. *Virology* **46**:691–702.
- Taylor, A., S. Kedzierska, and A. Wawrzynow. 1996. Bacteriophage lambda lysis gene product modified and inserted into *Escherichia coli* outer membrane: Rz1 lipoprotein. *Microb. Drug Resist.* **2**:147–153.
- Van Dyk, T. K., Y. Wei, M. K. Hanafey, M. Dolan, M. J. Reeve, J. A. Rafalski,

- L. B. Rothman-Denes, and R. A. LaRossa. 2001. A genomic approach to gene fusion technology. *Proc. Natl. Acad. Sci. USA* **98**:2555–2560.
39. Weisberg, R. A., and M. E. Gottesman. 1999. Processive antitermination. *J. Bacteriol.* **181**:359–367.
40. Wood, L. F., N. Y. Tszine, and G. E. Christie. 1997. Activation of P2 late transcription by P2 Ogr protein requires a discrete contact site on the C terminus of the  $\alpha$  subunit of *Escherichia coli* RNA polymerase. *J. Mol. Biol.* **274**:1–7.
41. Young, R. 1992. Bacteriophage lysis: mechanism and regulation. *Microbiol. Rev.* **56**:430–481.
42. Young, R., S. Way, J. Yin, and M. Syvanen. 1979. Transposition mutagenesis of bacteriophage lambda: a new gene affecting cell lysis. *J. Mol. Biol.* **132**:307–322.
43. Zhang, N., and R. Young. 1999. Complementation and characterization of the nested Rz and Rz1 reading frames in the genome of bacteriophage lambda. *Mol. Gen. Genet.* **262**:659–667.
44. Ziermann, R., B. Bartlett, R. Calendar, and G. E. Christie. 1994. Functions involved in bacteriophage P2-induced host cell lysis and identification of a new tail gene. *J. Bacteriol.* **176**:4974–4984.